Gene-Based Therapy for Cancer: Brain Tumors

[1]  P. Grandi,et al.  Design and application of oncolytic HSV vectors for glioblastoma therapy , 2009, Expert review of neurotherapeutics.

[2]  J. Markert,et al.  Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  Santosh Kesari,et al.  Malignant gliomas in adults. , 2008, The New England journal of medicine.

[4]  S. Russell,et al.  Measles virus as an oncolytic vector platform. , 2008, Current gene therapy.

[5]  B. Thompson,et al.  A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  F. Lang,et al.  Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  Chiocca Ea.  The host response to cancer virotherapy. , 2008 .

[8]  E. Chiocca.  The host response to cancer virotherapy. , 2008, Current opinion in molecular therapeutics.

[9]  W. Yung,et al.  Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter. , 2007, Cancer research.

[10]  C. James,et al.  Combination of Measles Virus Virotherapy and Radiation Therapy Has Synergistic Activity in the Treatment of Glioblastoma Multiforme , 2007, Clinical Cancer Research.

[11]  L. Chin,et al.  Malignant astrocytic glioma: genetics, biology, and paths to treatment. , 2007, Genes & development.

[12]  H. Colman,et al.  Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. , 2007, Journal of the National Cancer Institute.

[13]  C. Hartmann,et al.  Combined treatment of pediatric high‐grade glioma with the oncolytic viral strain MTH‐68/H and oral valproic acid , 2006, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[14]  H. Pelicano,et al.  Glycolysis inhibition for anticancer treatment , 2006, Oncogene.

[15]  F. Lang,et al.  Oncolytic adenoviruses as antiglioma agents , 2006, Expert review of anticancer therapy.

[16]  R. Martuza,et al.  Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. , 2006, Journal of the National Cancer Institute.

[17]  J. Gomori,et al.  Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  E. Chiocca,et al.  Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus. , 2005, Cancer research.

[19]  T. Hermiston,et al.  Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects. , 2005, Seminars in oncology.

[20]  G. Palù,et al.  Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results , 2005, Cancer Gene Therapy.

[21]  M. Boyd,et al.  Assessment in vitro of a novel therapeutic strategy for glioma, combining herpes simplex virus HSV1716-mediated oncolysis with gene transfer and targeted radiotherapy. , 2005, Medicinal chemistry (Shariqah (United Arab Emirates)).

[22]  J. Markert,et al.  Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model. , 2005, Neuro-oncology.

[23]  W. Yung,et al.  Δ24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization , 2005, Cancer Gene Therapy.

[24]  O. Wildner.  Clinical trials: The sensitizing side of Onyx-015 , 2005, Gene Therapy.

[25]  F. McCormick,et al.  Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. , 2004, Cancer cell.

[26]  S. Ylä-Herttuala,et al.  AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[27]  J. Olson,et al.  A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[28]  S. Brown,et al.  HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival , 2004, Gene Therapy.

[29]  B. Bodey,et al.  MTH-68/H Oncolytic Viral Treatment in Human High-Grade Gliomas , 2004, Journal of Neuro-Oncology.

[30]  D. Benos,et al.  Oncolytic Viruses: Clinical Applications as Vectors for the Treatment of Malignant Gliomas , 2003, Journal of Neuro-Oncology.

[31]  Z. Fishelson,et al.  Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. , 2003, Molecular immunology.

[32]  Susan M. Chang,et al.  Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  P. Mishra,et al.  Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. , 2003, Cancer research.

[34]  G. Fuller,et al.  Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. , 2003, Journal of the National Cancer Institute.

[35]  S. Hirschfeld,et al.  Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  F. McCormick,et al.  Cancer Specific Viruses and the Development of ONYX-015 , 2003, Cancer biology & therapy.

[37]  B. Sangro,et al.  Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. , 2003, Current gene therapy.

[38]  G. Palù,et al.  Gene therapy of thyroid cancer via retrovirally-driven combined expression of human interleukin-2 and herpes simplex virus thymidine kinase. , 2003, European journal of endocrinology.

[39]  G. Palù,et al.  Transcriptionally targeted retroviral vector for combined suicide and immunomodulating gene therapy of thyroid cancer. , 2002, The Journal of clinical endocrinology and metabolism.

[40]  R. Petty,et al.  The potential for efficacy of the modified (ICP 34.5−) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study , 2002, Gene Therapy.

[41]  F. Farassati,et al.  Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1 , 2001, Nature Cell Biology.

[42]  S. Nishikawa,et al.  Reovirus as an oncolytic agent against experimental human malignant gliomas. , 2001, Journal of the National Cancer Institute.

[43]  R. Alemany,et al.  A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  N. Rainov.  A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. , 2000, Human gene therapy.

[45]  Nahum Sonenberg,et al.  Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus , 2000, Nature Medicine.

[46]  R. Martuza,et al.  Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial , 2000, Gene Therapy.

[47]  A. Maclean,et al.  Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma , 2000, Gene Therapy.

[48]  J. Markert,et al.  Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[49]  T. McDonnell,et al.  A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo , 2000, Oncogene.

[50]  T. Bakács,et al.  Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma. , 1999, JAMA.

[51]  V. Schirrmacher,et al.  Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus , 1999, Gene Therapy.

[52]  V. Schirrmacher,et al.  Introduction of adhesive and costimulatory immune functions into tumor cells by infection with Newcastle Disease Virus. , 1998, International journal of oncology.

[53]  G. Palù,et al.  Production and characterization of a bicistronic Moloney-based retroviral vector expressing human interleukin 2 and herpes simplex virus thymidine kinase for gene therapy of cancer , 1998, Gene Therapy.

[54]  M. Coffey,et al.  The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus , 1998, The EMBO journal.

[55]  A. Pawson,et al.  Proliferation of human malignant astrocytomas is dependent on Ras activation , 1997, Oncogene.

[56]  D. Kirn,et al.  ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents , 1997, Nature Medicine.

[57]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[58]  B. Roizman,et al.  The γ134.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1α to dephosphorylate the α subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase , 1997 .

[59]  B. Roizman,et al.  The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[60]  A. Fattaey,et al.  An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells , 1996, Science.

[61]  B. Roizman,et al.  The function of herpes simplex virus genes: a primer for genetic engineering of novel vectors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[62]  J. Trojanowski,et al.  Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. , 1995, Laboratory investigation; a journal of technical methods and pathology.

[63]  R. Martuza,et al.  Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas , 1995, Nature Medicine.

[64]  J. Roth,et al.  Safety Evaluation of Ad5CMY-p53 In Vitro and In Vivo , 1995 .

[65]  J. Roth,et al.  Safety evaluation of Ad5CMV-p53 in vitro and in vivo. , 1995, Human gene therapy.

[66]  F. Gage,et al.  Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[67]  H. Kirchner,et al.  Induction of cytokines and cytotoxicity against tumor cells by Newcastle disease virus. , 1994, Cancer biotherapy.

[68]  S. Shamah,et al.  Dominant-negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells , 1993, Molecular and cellular biology.

[69]  J. Roth,et al.  Generation and identification of recombinant adenovirus by liposome-mediated transfection and PCR analysis. , 1993, BioTechniques.

[70]  E. Harlow,et al.  Cellular targets for transformation by the adenovirus E1A proteins , 1989, Cell.

[71]  G. Unsgaard,et al.  Amplification of the epidermal growth factor receptor gene in biopsy specimens from human intracranial tumours. , 1988, British journal of neurosurgery.

[72]  Hermona Soreq,et al.  Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin , 1985, Nature.

[73]  W. H. Allan,et al.  Newcastle disease virus pathotypes. , 1974, Avian pathology : journal of the W.V.P.A.

[74]  J. Dingle,et al.  OBSERVATIONS ON THE REPEATED ADMINISTRATION OF VIRUSES TO A PATIENT WITH ACUTE LEUKEMIA. A PRELIMINARY REPORT. , 1964, The New England journal of medicine.